阿立哌唑治疗奥氮平所致精神分裂症患者体质量增加的随机双盲对照研究

摘要

目的：探讨阿立哌唑干预奥氮平所致体质量增加的有效性及安全性。方法：将服用单一奥氮平治疗所致体质量增加≥7％的入组对象72例随机分为 A 组（加服阿立哌唑10 mg 组，36例）及 B安慰剂组（36例），入组时、治疗4周及8周分别测定体质量、体质量指数（BMI）、空腹血糖（FG）、总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白（LDL）及高密度脂蛋白（HDL），并用阳性和阴性症状量表（PAN-SS）评定精神症状。结果：两组治疗前体质量、BMI、FG、TC、TG、LDL、HDL，差异无统计学意义（P ﹥0.05）。与治疗前比较，治疗8周，A 组体质量、BMI、FG 均明显下降（P ﹤0.05或 P ﹤0.01），而 HDL 有明显增高（P ﹤0.05）；B 组体质量、BMI、FG 均明显增高（P ﹤0.05或 P ﹤0.01）。治疗4周体质量、BMI 的变化值、治疗第8周体质量、BMI、FG、HDL 的变化值，两组均差异有统计学意义（P ﹤0.05或 P ﹤0.01）。结论：阿立哌唑能有效减轻奥氮平所致体质量增加和糖脂代谢紊乱。%ObJective:To explore the efficacy and safety of aripiprazole on body weight gain caused by olanzapine in patients with schizophrenia. Method:Seventy two patients with schizophrenia treated by olanza-pine whose weight gain more than 7 percents were randomly divided into A group(combined with aripiprazole 10 mg/ d,n = 36)and B group(placebo group,n = 36). The weight,body mass index(BMI),fasting blood-glu-cose(FG),total cholesterol( TC),triglyceride( TG),low density cholesterol( LDL),high density cholesterol (HDL)were tested at the beginning,the 4th and 8th weekend,and symptoms were assessed using positive and negative symptom scale(PANSS). Results:The weight,BMI,FG,TC,TG,LDL,HDL of two group had no significant differences at the beginning(P ﹥ 0. 05). After the treatment,the weight,BMI,FG decreased signifi-cantly at the 8th weekend in A group( P ﹤ 0. 05 or P ﹤ 0. 01),while the HDL elevated significantly( P ﹤0. 05). The weight,BMI,FG elevated significantly in B group(P ﹤ 0. 05 or P ﹤ 0. 01). The change of weight and BMI in two groups had significant differences at the 4th weekend. The change of weight,BMI,FG and HDL in two groups had significant differences at the 8th weekend. Conclusion:Aripiprazole treatment can relieve the body weight gain and metabolic side effects caused by olanzapine.